Medicine and Dentistry
Magnetic Resonance Imaging
100%
PET-MRI
93%
Neuroendocrine Tumor
93%
Chemoradiotherapy
93%
Positron Emission Tomography
60%
Ovary Metastasis
58%
Positron Emission Tomography-Computed Tomography
54%
Midgut
51%
Treatment Response
46%
Fluorodeoxyglucose F 18
46%
Esophageal Cancer
46%
Gallium 68
46%
Tetraxetan
46%
Cholangiocarcinoma
46%
Clinical Management
46%
Hepatocellular Carcinoma
46%
Metastatic Carcinoma
46%
Lutetium 177
46%
Castration Resistant Prostate Cancer
46%
Esophageal Cancer
46%
Intention-to-Treat Analysis
46%
Image Quality
36%
Overall Survival
36%
Neoplasm
32%
Clinical Decision Making
26%
Fluorine-18
26%
Tumor Progression
17%
Peptide Receptor
17%
Radionuclide Therapy
17%
Computer Assisted Tomography
16%
Polyethylene Terephthalate
16%
Progression Free Survival
15%
Targeted Radionuclide Therapy
15%
Esophagectomy
15%
Final Diagnosis
13%
Patient-Data
10%
Adverse Event
10%
Cancer
10%
Rank Sum Test
9%
Patient Referral
8%
Primary Tumor
8%
Postoperative Complication
7%
Shared Decision Making
7%
Carcinoma
7%
Survival Rate
7%
Surgical Mortality
7%
Endoscopic Biopsy
7%
Hazard Ratio
7%
Comorbidity
7%
Patient Counseling
7%
Pharmacology, Toxicology and Pharmaceutical Science
Esophagus Cancer
46%
Chemoradiation Therapy
46%
Fluorodeoxyglucose F 18
46%
Neuroendocrine Tumor
46%
Etidronic Acid
46%
Hyaluronidase
46%
Extravasation
46%
Technetium 99m
46%
Polyethylene Terephthalate
46%
Castration Resistant Prostate Cancer
46%
Lutetium 177
46%
Radioisotope
33%
Receptor
17%
Tumor Growth
17%
Progression Free Survival
15%
Neoplasm
14%
Adverse Event
10%
Primary Tumor
7%
Pet Animal
7%
Somatostatin Derivative
7%
Overall Survival
5%
Androgen Receptor
5%
Taxane
5%
Radioligand
5%
Clinical Trial
5%
Xerostomia
5%
Chemotherapy
5%
Retrospective Study
5%